CN109122869A - A kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect - Google Patents
A kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect Download PDFInfo
- Publication number
- CN109122869A CN109122869A CN201810898530.0A CN201810898530A CN109122869A CN 109122869 A CN109122869 A CN 109122869A CN 201810898530 A CN201810898530 A CN 201810898530A CN 109122869 A CN109122869 A CN 109122869A
- Authority
- CN
- China
- Prior art keywords
- milk
- lactobacillus
- hypertension
- preparation
- bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 71
- 230000000694 effects Effects 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 49
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 49
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 48
- 239000008267 milk Substances 0.000 claims abstract description 73
- 239000000843 powder Substances 0.000 claims abstract description 73
- 235000013336 milk Nutrition 0.000 claims abstract description 72
- 210000004080 milk Anatomy 0.000 claims abstract description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 241000894006 Bacteria Species 0.000 claims abstract description 54
- 241000186660 Lactobacillus Species 0.000 claims abstract description 43
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 33
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 31
- 240000008892 Helianthus tuberosus Species 0.000 claims abstract description 27
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims abstract description 27
- 239000002131 composite material Substances 0.000 claims abstract description 27
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 22
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 21
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 21
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 21
- 239000000944 linseed oil Substances 0.000 claims abstract description 21
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 21
- 239000008170 walnut oil Substances 0.000 claims abstract description 21
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 18
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 18
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 18
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 18
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 18
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 18
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 18
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 18
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 18
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 18
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 18
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 18
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 17
- 239000004310 lactic acid Substances 0.000 claims abstract description 17
- 235000015097 nutrients Nutrition 0.000 claims abstract description 10
- 238000012545 processing Methods 0.000 claims abstract description 10
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 239000006041 probiotic Substances 0.000 claims description 29
- 235000018291 probiotics Nutrition 0.000 claims description 29
- 239000003094 microcapsule Substances 0.000 claims description 25
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 22
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 22
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 22
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 21
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 21
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 21
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 21
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 20
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 17
- 235000010413 sodium alginate Nutrition 0.000 claims description 17
- 239000000661 sodium alginate Substances 0.000 claims description 17
- 229940005550 sodium alginate Drugs 0.000 claims description 17
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 15
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000012423 maintenance Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 241001478240 Coccus Species 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 12
- 239000008103 glucose Substances 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 238000009700 powder processing Methods 0.000 abstract description 2
- 230000011218 segmentation Effects 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 241001092040 Crataegus Species 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 102000004139 alpha-Amylases Human genes 0.000 description 12
- 108090000637 alpha-Amylases Proteins 0.000 description 12
- 229940024171 alpha-amylase Drugs 0.000 description 12
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 12
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 235000008476 powdered milk Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940079877 pyrogallol Drugs 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- -1 microelement Natural products 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- OWVNHBRJANEEKY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;hydrochloride Chemical compound Cl.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OWVNHBRJANEEKY-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/133—Fruit or vegetables
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect, belongs to milk powder processing technique field, in terms of mass fraction, including 100 parts of skimmed milk, 0.01~0.1 part of compound lactobacillus, 1~5 part of jerusalem artichoke powder, 0.1~0.5 part of oligofructose, 1~5 part of instant bean, 0.01~0.1 part of hawthorn powder, 0.001~0.01 part of conjugated linoleic acid, 0.001~0.01 part of linseed oil, 0.001~0.01 part of walnut oil, 0.001~0.005 part of L-carnitine.The formula of the milk powder, which uses, has the multi-sources function factor organic composites such as reducing blood lipid, blood pressure and blood glucose；Using different material segmentation addition, the wet processing that lactic acid bacteria is added after being embedded produces preparation method.The present invention can keep the health efficacy of added nutrient to greatest extent, and organoleptic properties are good, shelf-stable, and bacterium activity is high, lower hyperlipidemia, hypertension, hyperglycemia significant effect.
Description
Technical field
The invention belongs to milk powder processing technique fields, and in particular to a kind of formula milk and its system with lower hyperlipidemia, hypertension, hyperglycemia effect
Preparation Method.
Background technique
Milk powder be lactogenesis through the processing of the techniques such as impurity screening, heating, sterilization, standardization, homogeneous, concentration, spray drying and
At dairy products be easy to be absorbed by the body because its is full of nutrition, be suitable for that various people are edible, and are loved by consumers.
Formula milk is needed to design according to human body Different Nutrition element and adds manufactured milk powder, nutrition using genuine milk as primary raw material
It is abundant, it is vdiverse in function, the various needs of people are able to satisfy, are played an important role in the healthy growth growth course of human body.
Currently, most formula milks primarily to meet the nutritional need of baby, remove in milk powder and do not meet baby
The ingredient that youngster is absorbed and utilized, and joined linoleic acid, linolenic acid, DHA (docosahexaenoic acid is commonly called as docosapentaenoic acid), AA (peanut
Tetraenoic acid), lactose, microelement, vitamin, certain amino acid, the various nutritional ingredients such as nucleotide or other compositions, to reach
Close to the effect of breast milk, therefore, also referred to as babies ' formula milk powder promotes the healthy development of infant.But it is currently in
In the epoch of rapid development, life and work rhythm is fast, and pressure is big, in addition the problems such as dietary structure, food safety, environment, hyperlipidemia,
The high crowd of hypertension and hyperglycemia etc. three is more and more, seriously endangers the health of modern.And it is directed to this kind of crowd's appropriate design
The formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect drunk, existing market were not related to.
The production method of formula milk is divided into two kinds of dry and wet.Dry production is the various nutrition by milk powder and addition
Plain dry powder blend is made, simple process, but since some nutrient additive amounts are few or intermiscibility is poor or oxidizable, so as to cause production
Dissolubility, brew, homogeneity, the storage characteristics of product reduce, and functionality weakens.The general technology of wet production is raw milk experience
Receive, filtering, purification, it is cooling after, various nutrients are added, after mixing homogeneous, then are made through sterilization, concentration, spray drying, and it is dry
Method compares, and the various nutrients that dissolubility, brew, the homogeneity of product are improved, but added are in processing such as sterilization repeatedly, concentrations
Make the reduction of its effect vulnerable to destroying or aoxidizing in the process, if being added to probiotics in formula, thallus is easily damaged, activity drop
It is low, it is not shelf-stable.
Summary of the invention
The purpose of the present invention is to provide a kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect, the milk powder
Formula is using with multi-sources function factor organic composites such as reducing blood lipid, blood pressure and blood glucose；Preparation method is using different material point
Duan Tianjia, the wet processing production that lactic acid bacteria is added after being embedded.The present invention can keep added nutrient to greatest extent
Health efficacy, and organoleptic properties are good, shelf-stable, and bacterium activity is high, lower hyperlipidemia, hypertension, hyperglycemia significant effect.
The present invention is to be achieved through the following technical solutions:
A kind of formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect disclosed by the invention, in terms of mass fraction, including skimmed milk 100
Part, 0.01~0.1 part of compound lactobacillus, 1~5 part of jerusalem artichoke powder, 0.1~0.5 part of oligofructose, 1~5 part of instant bean, hawthorn
0.01~0.1 part of powder, 0.001~0.01 part of conjugated linoleic acid, 0.001~0.01 part of linseed oil, walnut oil 0.001~0.01
Part, 0.001~0.005 part of L-carnitine.
Preferably, the compound lactobacillus is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long double qis
Bacillus and streptococcus thermophilus composition；Wherein, quantity used in each bacterium is equal in compound lactobacillus.
Preferably, the compound lactobacillus is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long double qis
Bacillus and streptococcus thermophilus composition；Wherein, total coccus quantity and total bacillus quantity ratio are 1:2 in compound lactobacillus.
The invention also discloses a kind of preparation methods of formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, comprising the following steps:
1) raw material preparation: in terms of mass fraction, 100 parts of extracting degreasing cream, 0.01~0.1 part of compound lactobacillus, jerusalem artichoke powder 1~
5 parts, 0.1~0.5 part of oligofructose, 1~5 part of instant bean, 0.01~0.1 part of hawthorn powder, conjugated linoleic acid 0.001~0.01
Part, 0.001~0.01 part of linseed oil, 0.001~0.01 part of walnut oil, 0.001~0.005 part of L-carnitine；
2) prepared by compound lactobacillus bacterium mud: dense to bacterium in 36 DEG C of ± 1 DEG C of constant temperature incubations after compound lactobacillus is activated
Degree reaches 108CFU/mL, thalline were collected by centrifugation, and compound lactobacillus bacterium mud is made；
3) prepared by lactobacillary milk turbid: conjugated linoleic acid, linseed oil and walnut oil being mixed, emulsion, Xiang Fu is made
It closes in lactic acid bacteria bacterium mud and emulsion is added, be sufficiently mixed uniformly until lactobacillary milk turbid is made by after oil package in phage surface；
Herein, the precipitating object amount or quiet after relying primarily on the homogeneity of lactobacillary milk turbid, standing made from observation of use senses
Delamination is postponed, while its structural property can be analyzed and determined by Electronic Speculum is micro-.Lactobacillary milk turbid formation mechenism: altogether
The emulsion that conjugated linoleic acid, linseed oil and walnut oil are mixed to prepare is oily phase, and compound lactobacillus bacterium mud is water phase, when by oil and
Water is put together to be vibrated fiercely, can be obtained emulsion, but emulsion obtained in this way and unstable, as long as placing piece
It carves, is just divided into two layers again, because the oil droplet to spread out can be voluntarily combined when mutually colliding, to obtain stable emulsus
Liquid, it is often necessary to the presence of third component, that is, emulsifier.The effect of emulsifier be to prevent by the resulting drop of mechanical dispersion from
Mutually coalescence.The present invention is not necessarily to additional emulsifier, with the milk casein and lactalbumin traveling in the skimmed milk that adds in being formulated
Emulsifier function, lactoprotein has parents' active (not only hydrophilic but also oleophylic) and relatively high surface-active, thus can take the lead in inhaling
It is attached to oil-water interfaces and constitutes interfacial film, so that system is more stable.
4) prepared by probiotics composite microcapsule: 10 portions of skimmed milks, 0.1 part of jerusalem artichoke powder, 0.1 part being added into lactobacillary milk turbid
Oligofructose adds sodium alginate, and after mixing, after handling 0.5~1h at 30 DEG C, 37 DEG C of 8~14h of maintenance are reached to bacterium is dense
To 1010When CFU/g, probiotics composite microcapsule is made；
5) compound concentrated milk preparation: instant bean, hawthorn powder and remaining jerusalem artichoke powder being added into remaining skimmed milk, molten
After solution, homogeneous, sterilization, being concentrated into solid content is 40%~60%, and compound concentrated milk is made；
6) prepared by target formula milk: probiotics composite microcapsule and L-carnitine being added into compound concentrated milk, dissolves,
The formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect is made in matter, spray drying.
Preferably, the compound lactobacillus is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long double qis
Bacillus and streptococcus thermophilus composition；Wherein: quantity used in each bacterium is equal in compound lactobacillus.
Preferably, the compound lactobacillus is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long double qis
Bacillus and streptococcus thermophilus composition, total coccus quantity and total bacillus quantity ratio are 1:2.
It is further preferred that compound lactobacillus activation processing is by lactobacillus bulgaricus, lactobacillus acidophilus, rhamnose cream
Bacillus, long Bifidobacterium Bifidum and streptococcus thermophilus are inoculated in MRS fluid nutrient medium, and initial bacterium number is made to maintain 106CFU/mL。
Preferably, in step 4), the sodium alginate of addition and the mass ratio of skimmed milk are 1:200.
Preferably, in step 5) and step 6), processing condition are as follows: 14~21MPa of pressure, 55~65 DEG C of temperature.
Preferably, in step 6), spray drying condition are as follows: 160~170 DEG C of inlet air temperature, 65~75 DEG C of temperature of outgoing air.
Compared with prior art, the invention has the following beneficial technical effects:
Formula milk disclosed by the invention with lower hyperlipidemia, hypertension, hyperglycemia effect be by skimmed milk (skimmed milk and sheep cream) with it is compound
Probiotics, prebiotics (jerusalem artichoke powder, oligofructose, instant bean), the hawthorn powder with the esterified food effect that disappears, and there is drop
Rouge, the healthy functions nutraceutical for controlling a variety of prone diseases such as weight and prevention cardiovascular and cerebrovascular disease, diabetes, hypertension are strong
It is formulated made of more than ten trophic function factor organic composite such as agent conjugated linoleic acid, linseed oil, walnut oil, L-carnitine
Milk powder.The intake of fat can be reduced in formula using skimmed milk；The compound lactobacillus of addition is probiotics, has and adjusts enteron aisle
Microbial flora reinforces body biological barrier, improves immunity of organisms, improves the effect of host health；The jerusalem artichoke powder of addition and
Oligofructose is not only prebiotics, can promote the growth of probiotics, and have good adjustment effect to blood glucose, blood lipid；It is instant
Bean powder not only contains quality plant albumen, but also contains multiple functions ingredient, has to hyperlipidemia, diabetes, coronary heart disease etc.
Good preventive and therapeutic effect；Hawthorn powder is integration of drinking and medicinal herbs object, full of nutrition, vdiverse in function, wherein the organic acid contained and reconciliation rouge
Enzyme can promote the digestion of fat food, and the drug ingedients such as contained mountain terpene and flavonoids can effectively prevent hyperlipidemia, high blood
Pressure, obesity, fatty liver etc.；Conjugated linoleic acid is as a kind of newfound nutrient, from anticancer to prevention cardiovascular disease, sugar
Urine disease, onto body weight control, almost modern prevents the indispensable healthy food of modern civilization diseases；Linseed oil mainly contains
There is alpha-linolenic acid, be essential fatty acid, there is antithrombotic, reducing blood lipid, nourishing brain cell, antitumor, adjusting vegetative nerve
The effects of；Fatty acid in walnut oil is mainly unsaturated fatty acid, is mainly made of linoleic acid plus linolenic acid, is the high blood of drop
The good merchantable brand of rouge, hypertension and hyperglycemia；L-carnitine is a kind of amino acid for promoting adipose conversion as energy, major physiological
Function is to promote adipose conversion at energy, reduces body fat, loses weight, be a kind of fat-reducing nutrient complementary goods.Of the invention
Formula milk has done the above-mentioned specific dosage of more than ten trophic functions factor and has sufficiently considered, and it is economic and practical to give significant effect
Formula rate.
Further, compound lactobacillus selects lactobacillus bulgaricus, streptococcus thermophilus, lactobacillus acidophilus, rhamnose
The Mixed Microbes of lactobacillus and bifidobacterium longum, lactobacillus bulgaricus and streptococcus thermophilus are the characteristic bacterium of lactic acid fermented
Group, in the definition of the yogurt in International Dairy Federation and China's national standard, zymophyte is exactly the combination of the two bacterium, and this hair
One of bright eating method of milk powder is exactly yogurt can be prepared with direct fermentation, therefore be added to the two bacterium.Another aspect root
Show that the beneficial flora type of human body dietary supplementation and quantity are more according to numerous studies document announcement and clinical test, health
Effect is more significant, and lactobacillus acidophilus, Lactobacillus rhamnosus and bifidobacterium longum are the advantages in infant and long-lived Intestinal
Beneficial flora, the present invention is by lactobacillus bulgaricus, streptococcus thermophilus, lactobacillus acidophilus, Lactobacillus rhamnosus and long bifid
Bacillus is combined into Mixed Microbes, and not only health efficacy is significant for manufactured milk powder, and can be used for existing wine yogurt.
The preparation method of formula milk disclosed by the invention is using different material segmentation addition, and lactic acid bacteria adds after being embedded
The wet processing production added, can keep the health efficacy of added nutrient to greatest extent.The main body of this method innovative point
It is present:
1. preparing emulsion using conjugated linoleic acid, linseed oil and walnut oil in formula, thallus and emulsion being mixed
It closes, forms probiotics emulsion, probiotics can be wrapped up by oil；
2. adding a certain amount of trehalose (sodium alginate) in preparation process, the purpose for adding trehalose is for shape
At probiotics composite microcapsule.Added trehalose be sodium alginate, a kind of polysaccharide carbohydrate of sodium alginate, not by two kinds
A kind of linear polymer of monosaccharide 1,4- α-L- guluronic acid (G) and 1,4- beta-D-mannuronic acid (M) composition of same type.
The present invention then utilizes the Ca in sodium alginate and skimmed milk2+The characteristic of small gel particle can be formed under suitable concentration, this
Invention uses outer addition Ca2+Method (Ca of the invention2+Ca in skimmed milk in formula2+), pass through Ca2+Replace Na+It can
Gel network is formed, then the curing process purpose carried out is exactly to form gel network micro-capsule.Therefore, it is added into emulsion
Skimmed milk, jerusalem artichoke powder, oligofructose and sodium alginate mix, and after 30 DEG C of 0.5~1h of curing process, certain time are maintained then may be used
The micro-capsule with three-decker is formed, internal layer is thallus, and middle layer is conjugated linoleic acid, linseed oil and walnut oil, and outer layer is
Jerusalem artichoke powder, oligofructose and trehalose play protective effect to thallus and oiliness functional component, while thallus can be dense wherein
Collection, bacterium is dense to can reach 1010CFU/g or more；
3. instant bean and hawthorn powder are added in skimmed milk, it can be made sufficiently to dissolve, then through homogeneous, sterilization and dense
Contracting, product sensory performance are good；
4. micro-capsule and L-carnitine are added when spray drying, probiotics, prebiotics and other function can be kept to greatest extent
The activity and functionality of the energy factor；
5. the organoleptic properties such as the formula milk dissolubility of this method preparation, brew, homogeneity are good, bacterium activity is high, shelf-stable,
Lower hyperlipidemia, hypertension, hyperglycemia significant effect.
Detailed description of the invention
Fig. 1 is the bacterium mud scanning electron microscope (SEM) photograph of obtained five kinds of bacterium；Wherein, (a) is lactobacillus bulgaricus, (b) is thermophilic
Lactobacillus lactis (c) is Lactobacillus rhamnosus, (d) is long Bifidobacterium Bifidum, (e) is streptococcus thermophilus；
Fig. 2 is by the lactic acid bacteria scanning electron microscope (SEM) photograph of oil package；
Fig. 3 is the probiotics scanning electron microscope (SEM) photograph being embedded in probiotics composite microcapsule；
Fig. 4 is the scanning electron microscope (SEM) photograph of formula milk prepared by the present invention；
Fig. 5 is degradation capability of the formula milk prepared by the present invention to cholesterol；
Fig. 6 is degradation capability of the formula milk prepared by the present invention to triglycerides；
Fig. 7 is rejection ability of the formula milk prepared by the present invention to alpha-glucosidase；
Fig. 8 is rejection ability of the formula milk prepared by the present invention to alpha-amylase；
Fig. 9 is formula milk prepared by the present invention to O2 -Clearance rate；
Figure 10 is formula milk prepared by the present invention to DPPH clearance rate.
Specific embodiment
Below with reference to specific embodiment, the present invention is described in further detail, it is described be explanation of the invention and
It is not to limit.
One, milk formula
Formula milk disclosed by the invention with lower hyperlipidemia, hypertension, hyperglycemia effect: in terms of mass fraction, including 100 parts of skimmed milk, it is multiple
0.01~0.1 part of lactic acid bacteria of conjunction, 1~5 part of jerusalem artichoke powder, 0.1~0.5 part of oligofructose, 1~5 part of instant bean, hawthorn powder 0.01
It is~0.1 part, 0.001~0.01 part of conjugated linoleic acid, 0.001~0.01 part of linseed oil, 0.001~0.01 part of walnut oil, left
0.001~0.005 part of carnitine of rotation.
The compound lactobacillus is lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and thermophilic
Five kinds of lactic acid bacterias of hot streptococcus lactis, source is commercial product.
Two, formula milk preparation process
The preparation process of formula milk disclosed by the invention with lower hyperlipidemia, hypertension, hyperglycemia effect, comprising the following steps:
Step 1: the preparation of thallus
By lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and five kinds of streptococcus thermophilus
After lactic acid bacteria is activated, Liquid Culture reaches 10 to bacterium is dense8When CFU/mL or more, thalline were collected by centrifugation, obtains bacterium mud；Referring to figure
1, it is the bacterium mud scanning electron microscope (SEM) photograph of five kinds of bacterium used, wherein (a) is lactobacillus bulgaricus, is (b) lactobacillus acidophilus, (c) is
Lactobacillus rhamnosus (d) is long Bifidobacterium Bifidum, is (e) streptococcus thermophilus, is in amplification factor for above-mentioned thallus as shown in the figure
Scanning electron microscope aspect graph under 6000 times.
Step 2: the preparation of lactobacillary milk turbid
Conjugated linoleic acid, linseed oil and walnut oil are mixed, emulsion is made, cream is added into compound lactobacillus bacterium mud
Change liquid, be uniformly mixed, after phage surface is by oil package, lactobacillary milk turbid can be obtained；By the lactic acid bacteria scanning of oil package
Electron microscope as shown in Fig. 2, for preparation scanning electron microscope micro- phenogram of the lactobacillary milk turbid under amplification factor 1000, can be with
It is clearly visible the feature that thallus is wrapped up.
Step 3: the preparation of probiotics composite microcapsule
Into lactobacillary milk turbid, 10 portions of skimmed milks of addition, 0.1 part of jerusalem artichoke powder, 0.1 part of oligofructose, sodium alginate (add
The mass ratio of the sodium alginate and skimmed milk that enter is 1:200), after mixing, after 30 DEG C of 0.5~1h of solidification, 37 DEG C of maintenance 12h,
When bacterium is dense reach 1010CFU/g or more when, probiotics composite microcapsule can be obtained.The micro-capsule of formation has three-decker, and internal layer is
Thallus, middle layer are mainly conjugated linoleic acid, linseed oil and walnut oil, and outer layer is mainly jerusalem artichoke powder and oligofructose；Referring to
Fig. 3 is micro- phenogram of the probiotics composite microcapsule under 3000 times of scanning electron microscope of amplification factor, it can be seen from the figure that bacterium
Body is wrapped up by skimmed milk, jerusalem artichoke powder, oligofructose, the trehalose etc. in formula.
Step 4: the preparation of compound concentrated milk
Instant bean, hawthorn powder and remaining jerusalem artichoke powder are added in 90 portions of skimmed milks to be concentrated into after dissolution, homogeneous, sterilization
When solid content is 40%~60%, compound concentrated milk can be obtained；
Step 5: the preparation of the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect
Probiotics composite microcapsule and L-carnitine are added in compound concentrated milk, quickly dissolution, homogeneous, spray drying, i.e.,
Formula milk can be obtained.As a result referring to fig. 4, Fig. 4 is micro- table of the milk powder of preparation under 2800 times of scanning electron microscope of amplification factor
Sign figure, it can be seen that have the distribution of a large amount of thallus in the prepared formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, and thallus is embedded
Among other components of milk powder, to improve the heat resistance and survival rate of bacterium.
Embodiment 1
A kind of formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect: in terms of mass fraction, including 100 parts of skimmed milk, compound lactobacillus
It is 0.05 part, 2 parts of jerusalem artichoke powder, 0.3 part of oligofructose, 3 parts of instant bean, 0.06 part of hawthorn powder, 0.005 part of conjugated linoleic acid, sub-
0.005 part of flaxseed oil, 0.005 part of walnut oil, 0.003 part of L-carnitine.
Wherein, compound lactobacillus by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and
Streptococcus thermophilus composition；Wherein: quantity used in each bacterium is equal in compound lactobacillus.
The preparation method of the above-mentioned formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, comprising the following steps:
Step 1: the preparation of thallus
By lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and five kinds of streptococcus thermophilus
After lactic acid bacteria is activated, reach 10 to bacterium is dense in 36 DEG C of ± 1 DEG C of constant temperature incubations8When CFU/mL or more, thalline were collected by centrifugation, obtains
Compound lactobacillus bacterium mud；
Step 2: the preparation of lactobacillary milk turbid
Conjugated linoleic acid, linseed oil and walnut oil are mixed, emulsion is made, cream is added into compound lactobacillus bacterium mud
Change liquid, be uniformly mixed, after phage surface is by oil package, lactobacillary milk turbid can be obtained；
Step 3: the preparation of probiotics composite microcapsule
Into lactobacillary milk turbid, 10 portions of skimmed milks of addition, 0.1 part of jerusalem artichoke powder, 0.1 part of oligofructose, sodium alginate (add
The mass ratio of the sodium alginate and skimmed milk that enter is 1:200), after mixing, after 30 DEG C of solidification 0.8h, 37 DEG C of maintenance 12h, to bacterium
It is dense to reach 1010When CFU/g or more, probiotics composite microcapsule can be obtained.
Step 4: the preparation of compound concentrated milk
Instant bean, hawthorn powder and remaining jerusalem artichoke powder, after dissolution, homogeneous, sterilization, concentration are added into remaining skimmed milk
To solid content be 50% when, compound concentrated milk can be obtained；
Step 5: the preparation of the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect
Probiotics composite microcapsule and L-carnitine are added in compound concentrated milk, quickly dissolution, homogeneous, spray drying, i.e.,
It can obtain the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect.
Embodiment 2
A kind of formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect: in terms of mass fraction, including 100 parts of skimmed milk, compound lactobacillus
It is 0.05 part, 2 parts of jerusalem artichoke powder, 0.3 part of oligofructose, 3 parts of instant bean, 0.06 part of hawthorn powder, 0.005 part of conjugated linoleic acid, sub-
0.005 part of flaxseed oil, 0.005 part of walnut oil, 0.005 part of L-carnitine.
Wherein, the compound lactobacillus is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long double qi bars
Bacterium and streptococcus thermophilus composition, total coccus quantity and total bacillus quantity ratio are 1:2.
The preparation method of the above-mentioned formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, comprising the following steps:
Step 1: the preparation of thallus
By lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and five kinds of streptococcus thermophilus
After lactic acid bacteria is activated, reach 10 to bacterium is dense in 36 DEG C of ± 1 DEG C of constant temperature incubations8When CFU/mL or more, thalline were collected by centrifugation, obtains
Compound lactobacillus bacterium mud；
Step 2: the preparation of lactobacillary milk turbid
Conjugated linoleic acid, linseed oil and walnut oil are mixed, emulsion is made, cream is added into compound lactobacillus bacterium mud
Change liquid, be uniformly mixed, after phage surface is by oil package, lactobacillary milk turbid can be obtained；
Step 3: the preparation of probiotics composite microcapsule
Into lactobacillary milk turbid, 10 portions of skimmed milks of addition, 0.1 part of jerusalem artichoke powder, 0.1 part of oligofructose, sodium alginate (add
The mass ratio of the sodium alginate and skimmed milk that enter is 1:200), after mixing, after 30 DEG C of solidification 1h, 37 DEG C of maintenance 14h are dense to bacterium
Reach 1010When CFU/g or more, probiotics composite microcapsule can be obtained.
Step 4: the preparation of compound concentrated milk
Instant bean, hawthorn powder and remaining jerusalem artichoke powder, after dissolution, homogeneous, sterilization, concentration are added into remaining skimmed milk
To solid content be 60% when, compound concentrated milk can be obtained；
Step 5: the preparation of the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect
Probiotics composite microcapsule and L-carnitine are added in compound concentrated milk, quickly dissolution, homogeneous, spray drying, i.e.,
It can obtain the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect.
Embodiment 3
A kind of formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect: in terms of mass fraction, including 100 parts of skimmed milk, compound lactobacillus
It is 0.01 part, 1 part of jerusalem artichoke powder, 0.1 part of oligofructose, 1 part of instant bean, 0.01 part of hawthorn powder, 0.001 part of conjugated linoleic acid, sub-
0.001 part of flaxseed oil, 0.001 part of walnut oil, 0.001 part of L-carnitine.
Compound lactobacillus is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and thermophilic cream
Streptococcus composition；Wherein: quantity used in each bacterium is equal in compound lactobacillus.
The preparation method of the above-mentioned formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, comprising the following steps:
Step 1: the preparation of thallus
By lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and five kinds of streptococcus thermophilus
After lactic acid bacteria is activated, reach 10 to bacterium is dense in 36 DEG C of ± 1 DEG C of constant temperature incubations8When CFU/mL or more, thalline were collected by centrifugation, obtains
Compound lactobacillus bacterium mud；
Step 2: the preparation of lactobacillary milk turbid
Conjugated linoleic acid, linseed oil and walnut oil are mixed, emulsion is made, cream is added into compound lactobacillus bacterium mud
Change liquid, be uniformly mixed, after phage surface is by oil package, lactobacillary milk turbid can be obtained；
Step 3: the preparation of probiotics composite microcapsule
Into lactobacillary milk turbid, 10 portions of skimmed milks of addition, 0.1 part of jerusalem artichoke powder, 0.1 part of oligofructose, sodium alginate (add
The mass ratio of the sodium alginate and skimmed milk that enter is 1:200), after mixing, after 30 DEG C of solidification 0.5h, 37 DEG C of maintenance 8h, to bacterium
It is dense to reach 1010When CFU/g or more, probiotics composite microcapsule can be obtained.
Step 4: the preparation of compound concentrated milk
Instant bean, hawthorn powder and remaining jerusalem artichoke powder, after dissolution, homogeneous, sterilization, concentration are added into remaining skimmed milk
To solid content be 450% when, compound concentrated milk can be obtained；
Step 5: the preparation of the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect
Probiotics composite microcapsule and L-carnitine are added in compound concentrated milk, quickly dissolution, homogeneous, spray drying, i.e.,
It can obtain the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect.
Three, inventive formulation milk powder functionality test experience
The degradation capability of cholesterol, the degradation capability of triglycerides, the rejection ability of alpha-glucosidase, alpha-amylase
Rejection ability removes O2 -The indexs such as ability and removing DPPH ability are evaluation product reducing blood lipid, hypoglycemic, blood pressure lowering important body
Outer index.
Below just from above-mentioned several indexs, test experience is carried out to formula milk function of the invention.
1, to the degradation capability of cholesterol and triglycerides
Powdered milk sample obtained above is added to containing in a certain amount of cholesterol or triglycerides solution respectively, in 36 DEG C
50h is placed under ± 1 DEG C of constant temperature, the amount of cholesterol or triglycerides is measured every 5h, draws time --- cholesterol or time ---
Content of triglyceride curve calculates milk powder to the degradation rate of cholesterol and triglycerides.Calculation formula is as follows:
In formula:
The degradation rate (%) of W --- cholesterol or triglyceride mass；
The cholesterol or triglyceride mass (g/L) of m --- reduction；
M --- total cholesterol or triglyceride mass (g/L).
As a result as shown in Figure 5 and Figure 6, cholesterol and triglycerides are two important indicators for evaluating hyperlipemia, amount
It is to suffer from hyperlipemic patients when height is to certain value, hyperlipidemia can cause the diseases such as hypertension and hyperglycemia, serious harm human health.
It can see from Fig. 5, Fig. 6, three batches of milk powder prepared by the present invention has certain resolution to act in cholesterol and triglycerides,
After processing 60 hours milk powder be respectively 22%, 19%, 21% and 24.9% to the degradation rate of cholesterol and triglycerides,
26.3%, 20.9%, illustrate that milk powder produced by the present invention has certain effect for reducing fat.
2, to the rejection ability of alpha-glucosidase, alpha-amylase
Powdered milk sample obtained above is added to the solution containing certain alpha-glucosidase or alpha-amylase activity respectively
In, about 72h is placed under 36 DEG C of ± 1 DEG C of constant temperature, measures alpha-glucosidase activity or alpha-amylase activity at regular intervals,
Enzyme activity inhibiting rate is calculated, time --- alpha-glucosaccharase enzyme inhibition rate or time --- alpha-amylase inhibiting rate curve is drawn.
Enzyme activity inhibiting rate calculation formula are as follows:
Enzyme activity/starting point enzyme activity of inhibiting rate=starting point certain time of enzyme activity-
Inhibition assay result to alpha-glucosidase is as shown in fig. 7, alpha-glucosidase is direct participation starch and sugar
Former metabolic pathway, releases glucose as product, and inhibition alpha-glucosidase can make starch be decomposed into the speed of glucose
Slow down, the absorption for reducing and delaying small intestine to glucose, it is obvious to the effect of postprandial hyperglycemia to reduce blood glucose.It can be with from Fig. 7
See, three batches of milk powder prepared by the present invention has certain inhibiting effect to alpha-glucosidase, at 72-hours post-treatment milk powder
Inhibiting rate to alpha-glucosidase is respectively 17.2%, 21.6% and 27.8%, illustrates that milk powder produced by the present invention has drop
Blood glucose effect.
Inhibition assay result to alpha-amylase is as shown in figure 8, after human body feed, main carbon aquation contained in food
Close object such as starch etc., can the hydrolysis generation short-chain carbohydrates substance such as various saccharides and schardinger dextrin Jing Guo alpha-amylase, then pass through again
The hydrolysis for crossing other carbohydrase generates glucose, makes one intracorporal blood glucose rise, diabetic is due to the benefit to internal blood glucose
With there is certain obstacle to increase internal blood glucose persistently, to generate the symptoms such as hyperglycemia, inhibit alpha-amylase activity, it can be
The digestion for hindering internal carbohydrate to a certain extent, reduces blood glucose, therefore is to prevent and control to the inhibition of alpha-amylase
Treat a kind of means of diabetes.As seen from Figure 8, three batches of milk powder prepared by the present invention has preferable inhibition to alpha-amylase
Effect, milk powder has respectively reached 50.1%, 58.6% and 65.3% to the inhibiting rate of alpha-amylase after processing 70 hours, inhibits
Significant effect illustrates that milk powder hypoglycemic effect produced by the present invention is significant.
3, O is removed2 -Ability
The Tris-HCl-EDTA buffer that 4mL is added in 1g powdered milk sample obtained above, pH value is 8.2 is taken, in 25 DEG C of water
The HCl for bathing 5mmol/L is added after 25min pyrogallol solution 25 DEG C of water-baths 10min, rear 0.1mL 8mol/L terminates reaction,
And its absorbance is measured at 420nm.
O2 -Clearance rate calculation formula are as follows:
In formula:
A is sample sets: containing sample solution and pyrogallol solution；
B is sample blank group: containing sample solution, being free of pyrogallol solution；
C is control: not containing sample solution, solution containing pyrogallol；
D is blank group: not containing sample solution and pyrogallol solution.
4, DPPH ability is removed
Take 1g powdered milk sample obtained above to be added the DPPH of 10mL 0.2mmol/L, setting sample blank group with compare
Group replaces DPPH and equivalent methanol to replace sample with equivalent methanol respectively.It returns to zero by blank of methanol, in 37 DEG C in dark
20min measures absorbance after 4000r/min is centrifuged at 519nm.
DPPH clearance rate calculation formula are as follows:
In formula:
A is sample sets: containing sample solution and DPPH solution；
B is sample blank group: being free of DPPH solution containing sample solution；
C is control group: not containing sample solution solution containing DPPH.
O2- clearance rate and DPPH clearance rate are the important indicator of anti-oxidation characteristics, clearance rate height and inoxidizability
Power, which is positively correlated, is, the negatively correlated system of disease incidence with hyperlipidemia, hypertension and hyperglycemia.It can see from Fig. 9, Figure 10,
Three batches of milk powder prepared by the present invention has certain scavenging effect to O2- and DPPH, and milk powder is to O2- clearance rate after 72 hours
45.2%, 35.1%, 30.6% and 60.8%, 71.5%, 82.3% have been respectively reached with DPPH clearance rate, has illustrated that the milk powder has
There are stronger antioxidation and lower hyperlipidemia, hypertension, hyperglycemia effect.
It in summary it can be seen, by the analysis detection of the lower hyperlipidemia, hypertension, hyperglycemia index of the formula milk prepared to this law, show the method
The milk powder of preparation has significant lower hyperlipidemia, hypertension, hyperglycemia effect.
Claims (10)
1. a kind of formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that in terms of mass fraction, including 100 parts of skimmed milk, it is multiple
0.01~0.1 part of lactic acid bacteria of conjunction, 1~5 part of jerusalem artichoke powder, 0.1~0.5 part of oligofructose, 1~5 part of instant bean, hawthorn powder 0.01
It is~0.1 part, 0.001~0.01 part of conjugated linoleic acid, 0.001~0.01 part of linseed oil, 0.001~0.01 part of walnut oil, left
0.001~0.005 part of carnitine of rotation.
2. according to claim 1 with the formula milk of lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that the compound lactobacillus is by protecting
Add Leah lactobacillus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and streptococcus thermophilus composition；Wherein, Composite Milk
Quantity used in each bacterium is equal in sour bacterium.
3. according to claim 1 with the formula milk of lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that the compound lactobacillus is by protecting
Add Leah lactobacillus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and streptococcus thermophilus composition；Wherein, Composite Milk
Total coccus quantity and total bacillus quantity ratio are 1:2 in sour bacterium.
4. a kind of preparation method of the formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect, which comprises the following steps:
1) raw material preparation: in terms of mass fraction, 100 parts of extracting degreasing cream, 0.01~0.1 part of compound lactobacillus, 1~5 part of jerusalem artichoke powder,
0.1~0.5 part of oligofructose, 1~5 part of instant bean, 0.01~0.1 part of hawthorn powder, 0.001~0.01 part of conjugated linoleic acid,
0.001~0.01 part of linseed oil, 0.001~0.01 part of walnut oil, 0.001~0.005 part of L-carnitine；
2) prepared by compound lactobacillus bacterium mud: after compound lactobacillus is activated, reaching in 36 DEG C of ± 1 DEG C of constant temperature incubation to bacteria concentrations
To 108CFU/mL, thalline were collected by centrifugation, and compound lactobacillus bacterium mud is made；
3) prepared by lactobacillary milk turbid: conjugated linoleic acid, linseed oil and walnut oil being mixed, emulsion is made, to Composite Milk
Emulsion is added in sour bacterium bacterium mud, is sufficiently mixed uniformly until lactobacillary milk turbid is made by after oil package in phage surface；
4) probiotics composite microcapsule prepare: into lactobacillary milk turbid be added 10 portions of skimmed milks, 0.1 part of jerusalem artichoke powder, 0.1 part it is oligomeric
Fructose adds sodium alginate, and after mixing, after handling 0.5~1h at 30 DEG C, 37 DEG C of 8~14h of maintenance reach to bacterium is dense
1010When CFU/g, probiotics composite microcapsule is made；
5) compound concentrated milk preparation: instant bean, hawthorn powder and remaining jerusalem artichoke powder are added into remaining skimmed milk, dissolves,
After matter, sterilization, being concentrated into solid content is 40%~60%, and compound concentrated milk is made；
6) prepared by target formula milk: probiotics composite microcapsule and L-carnitine are added into compound concentrated milk, dissolves, homogeneous,
The formula milk with lower hyperlipidemia, hypertension, hyperglycemia effect is made in spray drying.
5. the preparation method of the formula milk according to claim 4 with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that described multiple
Lactic acid bacteria is closed by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and streptococcus thermophilus group
At；Wherein: quantity used in each bacterium is equal in compound lactobacillus.
6. the preparation method of the formula milk according to claim 4 with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that described multiple
Lactic acid bacteria is closed by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and streptococcus thermophilus group
At total coccus quantity and total bacillus quantity ratio are 1:2.
7. the preparation method of the formula milk according to claim 5 or 6 with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that multiple
Closing lactic acid bacteria and being activated is by lactobacillus bulgaricus, lactobacillus acidophilus, Lactobacillus rhamnosus, long Bifidobacterium Bifidum and thermophilic cream
Streptococcus is inoculated in respectively in MRS fluid nutrient medium, and initial bacterium number is made to maintain 106CFU/mL。
8. the preparation method of the formula milk according to claim 4 with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that step 4)
In, the sodium alginate of addition and the mass ratio of skimmed milk are 1:200.
9. the preparation method of the formula milk according to claim 4 with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that step 5)
With in step 6), processing condition are as follows: 14~21MPa of pressure, 55~65 DEG C of temperature.
10. the preparation method of the formula milk according to claim 4 with lower hyperlipidemia, hypertension, hyperglycemia effect, which is characterized in that step
6) in, spray drying condition are as follows: 160~170 DEG C of inlet air temperature, 65~75 DEG C of temperature of outgoing air.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810898530.0A CN109122869A (en) | 2018-08-08 | 2018-08-08 | A kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810898530.0A CN109122869A (en) | 2018-08-08 | 2018-08-08 | A kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109122869A true CN109122869A (en) | 2019-01-04 |
Family
ID=64792234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810898530.0A Pending CN109122869A (en) | 2018-08-08 | 2018-08-08 | A kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109122869A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112425655A (en) * | 2020-11-24 | 2021-03-02 | 吴兆盈 | Formula milk powder for preventing hyperlipidemia, hyperglycemia and hypertension and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545936A (en) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | Edible combination containing active Lactobacillus paracasei and preparation method thereof |
| US20100278975A1 (en) * | 2008-01-25 | 2010-11-04 | Cell Biotech Co., Ltd. | Method of preparing triple-coating lactic acid bacteria and nano particle coating method, triple-coating lactic acid bacteria prepared thereby and article comprising the same |
| CN104000025A (en) * | 2014-06-11 | 2014-08-27 | 北京昕地美饲料科技有限公司 | Method for making stabilized lactic acid bacteria product |
| CN104542974A (en) * | 2015-01-29 | 2015-04-29 | 王维义 | Omega-3 yoghurt powder and preparation process thereof |
| CN105285983A (en) * | 2015-10-27 | 2016-02-03 | 江西美庐乳业集团有限公司 | Weight losing and slimming nutrition package |
-
2018
- 2018-08-08 CN CN201810898530.0A patent/CN109122869A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545936A (en) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | Edible combination containing active Lactobacillus paracasei and preparation method thereof |
| US20100278975A1 (en) * | 2008-01-25 | 2010-11-04 | Cell Biotech Co., Ltd. | Method of preparing triple-coating lactic acid bacteria and nano particle coating method, triple-coating lactic acid bacteria prepared thereby and article comprising the same |
| CN104000025A (en) * | 2014-06-11 | 2014-08-27 | 北京昕地美饲料科技有限公司 | Method for making stabilized lactic acid bacteria product |
| CN104542974A (en) * | 2015-01-29 | 2015-04-29 | 王维义 | Omega-3 yoghurt powder and preparation process thereof |
| CN105285983A (en) * | 2015-10-27 | 2016-02-03 | 江西美庐乳业集团有限公司 | Weight losing and slimming nutrition package |
Non-Patent Citations (2)
| Title |
|---|
| 孙记录 等: ""菊芋在脱脂乳中对双歧杆菌生长的影响研究"", 《中国微生态学杂志》 * |
| 李再新 等: ""脱脂奶粉对微囊化乳酸菌保护的研究"", 《江苏农业科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112425655A (en) * | 2020-11-24 | 2021-03-02 | 吴兆盈 | Formula milk powder for preventing hyperlipidemia, hyperglycemia and hypertension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
| CN111406856B (en) | Functional fermented beverage for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN106173773A (en) | A kind of ferment probiotic bacteria solid beverage and preparation method thereof | |
| CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
| CN102511861A (en) | Thickened red jujube pulp added with oligosaccharide | |
| CN107019211A (en) | Prepare the fermentation composition and preparation method of the plant enzyme with the strong renal function of kidney tonifying | |
| CN108685006A (en) | A kind of 3 solid beverage of omega | |
| CN106858577A (en) | Prepare the fermentation composition and preparation method of the plant enzyme with liver protecting, the fatty subtotal hepatectomy of regulation | |
| CN104839684A (en) | Medical formula food for people with helicobacter pylori related gastritis | |
| CN105030950B (en) | The probiotics and its preparation method and application for preventing and treating hyperlipidemia | |
| CN102511864A (en) | Jujube high-consistency stock | |
| CN108936628A (en) | A kind of specific full nutritional formulas and preparation method thereof that patients with cerebral apoplexy is edible | |
| CN102742653A (en) | Brain-strengthening and nerve soothing probiotic goat milk tablet and preparation method of brain-strengthening and nerve soothing probiotic goat milk tablet | |
| CN105802876B (en) | A kind of composite probiotics ferment clover tender shoots powder preparation and its preparation method and application | |
| CN109122869A (en) | A kind of formula milk and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia effect | |
| CN113349377A (en) | Slimming probiotic soft capsule and preparation method thereof | |
| CN104839673A (en) | Medical formula food for people with renal failure | |
| CN104839670A (en) | Specific endowment constitution medical formula food | |
| CN106880040A (en) | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients | |
| CN103918795A (en) | Tea polyphenols probiotics goat milk tablet and preparation method thereof | |
| CN102754695A (en) | Burdock probiotics goat milk slices and method for preparing same | |
| CN102742654B (en) | A kind of beauty-beautifying probiotic goat milk tablet and preparation method thereof | |
| CN104839654A (en) | Medical formula food for acne-removing | |
| CN104839682A (en) | Medical formula food used for women menopause delaying and conditioning | |
| CN105029406A (en) | Medical formula food for hysteromyoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |